The US FDA has approved depemokimab as an add-on maintenance therapy for individuals aged 12 years or older with severe asthma, according to a press release from manufacturer GlaxoSmithKline.

"Brittany's story is a testament to resilience (and) the strength of family ... Her family's love and support were essential ...

Asthma symptoms worsened in children in Vermont and upstate New York exposed to smoke from Canadian wildfires, according to a recent study by UVM.

The Food and Drug Administration (FDA) has approved Exdensur (depemokimab-ulaa), an interleukin-5 antagonist, for add-on maintenance treatment of severe asthma characterized by an eosinophilic ...

Kolkata: A surge in pneumonia and COPD patients has left several private hospitals close to full occupancy, leading to a ...

The FDA has approved Exdensur depemokimab-ulaa as an add-on maintenance therapy for severe asthma in patients aged 12 and older, supported by Phase III SWIFT trial data showing significant reductions ...

Indiana University School of Medicine researchers are taking a closer look at how young patients respond to biologic ...

The FDA has approved GSK’s Exdensur (depemokimab-ulaa) as an add-on maintenance therapy for adolescents and adults with severe asthma characterized by an eosinophilic phenotype. 1 ...

FDA approves 2-dose biologic Exdensur for severe eosinophilic asthma in patients 12 and older, reducing exacerbations and hospital visits.

Depemokimab-ulaa (Exdensur) is approved for severe asthma with an eosinophilic phenotype, offering protection with just two ...

The FDA approved depemokimab (Exdensur) as the first ultra-long-acting biologic with twice-yearly dosing approved for ...

The U.S. health regulator has approved GSK's add-on treatment for severe asthma, offering a less frequently dosed option, but ...